Intravenous immunoglobulin therapy of antiphospholipid syndrome

Y. Sherer, Y. Levy and Y. Shoenfeld

Department of Medicine ‘B’ and the Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer and Sackler Faculty of Medicine, Tel-Aviv University, Israel

Abstract

Objective. To review the role of intravenous immunoglobulin (IVIg) in antiphospholipid syndrome (APS).

Methods. A literature search was carried out for the immunopathogenesis of APS, laboratory evidence for the beneficial effect of IVIg in APS, and the clinical use of IVIg in APS.

Results. There is both laboratory and clinical evidence for the beneficial role of IVIg in APS. IVIg succeeded in in vitro inhibition of anticardiolipin antibodies and lupus anticoagulant, and in the amelioration of experimental APS. Although there are few case reports about IVIg therapy in the haematological manifestations of APS, most of the reports focus on the use of IVIg in the obstetric complications of APS. Hence, in several patient series the use of IVIg either solely or in combination with aspirin/heparin resulted in successful pregnancy outcome in the vast majority of APS patients with recurrent abortions. In addition, IVIg was also beneficial in antiphospholipid antibody-positive patients undergoing in vitro fertilization.

Conclusion. APS, an autoimmune disease whose main features are vascular thrombosis and pregnancy morbidity, is a good candidate for immunotherapy with IVIg that contains anti-idiotypes directed towards patients’ pathogenic antiphospholipid antibodies. Future research should determine when to use anticoagulation, IVIg or both in the treatment of APS.

Key words: Antiphospholipid syndrome, Aspirin, Heparin, Intravenous immunoglobulin, Recurrent pregnancy loss.

Intravenous immunoglobulins (IVIg) are currently used in autoimmunity for the treatment of immune thrombocytopenic purpura, Guillain–Barre syndrome, Kawasaki disease, and polymyositis/dermatomyositis. In addition, in several other autoimmune conditions there have been several reports about beneficial responses to IVIg therapy, e.g. systemic lupus erythematosus, vasculitis, factor VIII inhibitors [1–3]. Herein we review the use of IVIg for the treatment of patients with antiphospholipid syndrome (APS).

APS—definition and clinical manifestations

The definition of APS includes the presence of both clinical and laboratory criteria. In order to diagnose APS a patient should have at least one clinical manifestation (vascular thrombosis, pregnancy morbidity) and one typical serological finding [medium to high titres of anticardiolipin antibodies (aCL) or a positive lupus anticoagulant (LAC) test on two or more occasions at least 6 weeks apart] [4]. The manifestations of this syndrome can further include [5]: venous thrombosis—deep vein thrombosis, pulmonary thromboembolism, Budd–Chiari syndrome, renal vein thrombosis, and ocular thrombosis; arterial thrombosis—stroke, transient ischaemic attack, amaurosis, myocardial infarction, and limb ischaemia; thrombocytopenia and haemolytic anaemia; and other features—epilepsy, migraine, livedo reticularis, chorea, myelopathy, pulmonary hypertension, skin ulcers, Addison’s disease, heart valve disease, and ischaemic necrosis of bone. Pregnancy complications of APS include both maternal (pre-eclampsia/eclampsia) and fetal complications (early and late pregnancy loss, intrauterine growth retardation). Similarly, several autoantibodies, other than aCL, might be detected at APS, and these include antibodies directed to phosphatidyserine (PS), phosphatidyethanolamine (PE), phosphatidylinositol (PI), phosphatidylglycerol (PG), and phosphatidic acid. These antibodies comprise a group that binds beta-2-glycoprotein-I (beta-2GPI) in association with an acidic phospholipid. Nevertheless, antibodies directed solely to either beta-2GPI or...
prothrombin are also found in APS. Hence, the syndrome is termed APS rather than aCL syndrome.

The immunopathogenesis of APS

The association of an autoantibody with clinical manifestations of an autoimmune disease does not necessarily imply that it is of a pathogenic role. Nevertheless, with respect to antiphospholipid antibodies (aPL), there is good evidence that these antibodies are pathogenic in APS, rather than an epiphenomenon. As one of the major clinical manifestations of APS is thrombosis, aPL were found to interact with all the components of the coagulation system [6]. Regarding humoral component involvement, aPL were found to interfere with the activity of protein C, protein S cofactor and antithrombin III [7, 8], and to inhibit kallikrein formation from pre-kallikrein [9]. In addition, as beta-2GPI is a natural anticoagulant that inhibits the prothrombinase activity of platelets [10], binding of aCL to beta-2GPI can disturb its anticoagulant activities and consequently increase thrombin generation. Similarly, this antibody can alter the interference of beta-2GPI with ADP-induced platelet aggregation [11]. Thus, it has been shown that aCL attenuates the inhibitory effect of beta-2GPI on the formation of activated factor X in the presence of activated platelets [12]. aPL may also play a role in platelet activation in different ways: cross-reactivity of aCL with an 80-kDa platelet plasma membrane protein may in turn cause platelet activation [13], and similarly aPL can cause shape change and phosphorylation of 20-kDa protein that in turn may cause enhancement of thrombosis by increased thromboxane A2 formation, elevated cytosolic calcium concentration, and protein 47-kDa phosphorylation [14]. Furthermore, the interaction of aPL with PS on the surface of activated platelets may cause their subsequent destruction and uptake by the reticuloendothelial system, which may provide an explanation for the thrombocytopenia characteristic of APS [15]. With respect to the aPL effect on endothelial cells, increased procoagulant activity of endothelial cells and monocytes has been demonstrated in the presence of aPL [16, 17], and these antibodies also enhanced the production of platelet activating factor by endothelial cells [18]. Similarly, decreased production of prostaglandin I2, which is a potent vasodilator and inhibits platelet aggregation, has been found in association with LAC [19]. Another possible explanation for the thrombotic tendency in APS is an inhibition of anticoagulants by a cross-reaction of aPL with glycosaminoglycans, which are a major component of the non-thrombogenic lining of the vascular endothelium [20].

The most convincing evidence for a pathogenic role of aPL is their ability to induce APS in vivo in animal models [21]. Passive induction of APS entails the infusion of either monoclonal or polyclonal aPL to mice in order to create disease manifestations. Infusion of aCL (derived either from mice or humans) to pregnant ICR mice resulted in lower fecundity rate, increased resorption index of embryos, lower number of embryos per pregnancy, and lower weights of embryos and placentae than in the control mice [22]. Of specific interest is the pathogenic role of anti-PS antibodies demonstrated by passive induction of APS by Blank et al. [23]. They demonstrated the ability of polyclonal aPL to cause adverse effects on pregnancy outcome. Moreover, intravascular deposition of IgG and fibrin in the uteroplacental interface, absorption of aCL on placentae, and demonstration of thrombosis in placental vessels, further strengthen the pathogenic role of aPL in APS. Another way to induce APS is via active induction of disease. In short, when an antibody (Ab1) is either injected or generated in response to an autoantigen, its idiotype may stimulate the immune system to produce an antibody against it (Ab2). Consequently, anti-Ab2 (Ab3) may be generated too, and it can simulate the original autoantibody in its binding characteristics. Thus, following active immunization with a human pathogenic monoclonal IgM aCL (H-3), primary APS developed in BALB/c mice: the mice had high titres of aCL with clinical manifestations typical for APS [24]. Similarly, aPL obtained from patients with active APS, as well as monoclonal antibodies generated from mice with secondary systemic lupus erythematosus, succeeded in active induction of primary APS [25–27]. In addition, not only did passive transfer of anti-PS succeed in inducing APS, but active immunization with this antibody also had the same effect [28].

Laboratory evidence for the beneficial effect of IVIg in APS

Whereas other therapeutic options in APS inhibit the consequences of aPL activity (e.g. aspirin and heparin prevent the APS-associated thrombosis), IVIg both inhibits the aPL themselves, and probably decreases their further production. The inhibitory effect of IVIg on aPL, especially aCL, and LAC has been reported by several authors [29–32]. Caccavo et al. [29] reported the inhibition of aCL binding to cardiolipin by F(ab')2 fragment from IVIg in a dose-dependent manner. Similarly, Galli et al. [30] demonstrated dose-dependent inhibition of LAC activity in four patients, using either IVIg or F(ab')2 fragments from it. Finally, partial neutralization of LAC activity was found in 10 of 11 patient sera following incubation with IVIg [31]. These reports suggest the presence of anti-idiotypes to aPL within IVIg preparations. However, whereas anti-idiotypic activity of IVIg is probably the most important mechanism of action of IVIg in the treatment of APS, and it results in short-term neutralization of aPL, it certainly cannot explain the long-term decrease in these autoantibody titres. Hence, another mechanism of action of IVIg in APS involves the inactivation of idiotype-bearing B cell clones, with the subsequent decrease in autoantibody production.

The beneficial effect of IVIg in APS has been well demonstrated in animal models of the disease. Infusion of IVIg to mice in which the disease was induced, as previously discussed, resulted in significantly less fetal
Clinical use of IVIg in APS

Most of the reports about the use of IVIg in human APS focused on its obstetric complications, mainly recurrent pregnancy loss. Nonetheless, there are a few case reports about treatments of other clinical manifestations of the syndrome (mainly haematological), and these are summarized in Table 1. The first report of IVIg use for recurrent pregnancy loss was probably that of Carreras et al. [42] who reported a patient with a history of nine recurrent abortions, who following a 5-day course of 400 mg/kg body weight of IVIg at 17 weeks of gestation, followed by 2-day courses at 22 and 27 weeks of gestation gave birth to a healthy girl at 34 weeks of gestation. This report was followed by several other case reports of successful pregnancy outcome in APS patients with previous habitual abortions [43–46]. However, these cases varied much with respect to dose of IVIg, time of administration, and concomitant therapies used (e.g. heparin, aspirin, prednisone). Of special interest is the report of Rou-el et al. [46] of a patient with recurrent fetal loss, in whom a combined treatment with IVIg, aspirin and heparin, succeeded in the delivery of a healthy baby after transfer of frozen embryos.

Naturally, the case series would be much more valuable in the assessment of IVIg efficacy. Kaaja et al. [47] reported three APS patients whose history was remarkable for two pulmonary emboli, 13 miscarriages, and one live-born after pregnancy complicated with pre-eclampsia. The treatment of these three women with repetitive doses of IVIg 1 g/kg body weight combined with daily aspirin 75 mg, resulted in three deliveries of healthy babies at term, and one pre-term delivery (at 34 weeks of gestation). The IVIg therapy was also associated with progressive depression of IgG aCL titre. Similar results were reported by Spinnato et al. [48] who treated five APS patients (with 17 cumulative previous unsuccessful pregnancies) with monthly courses of IVIg 2 g/kg body weight beginning in the first or early second trimester. Four of them received concomitant heparin and/or aspirin. This treatment resulted in four deliveries of healthy babies at term, and one pre-term delivery (at 32 weeks of gestation). A decrease in IgG aCL titre was observed in three patients. As opposed to the good clinical outcome of pregnancies in the above reports, IVIg therapy in six women with recurrent abortions (five with APS and one with antinuclear antibody) resulted in three complicated twin pregnancies, and three pregnancies with intrauterine growth retardation [49]. However, following each IVIg infusion both IgG and IgM aCL titres significantly decreased. In a larger case series, Valensise et al. [50] reported 14 APS patients who received IVIg 1 g/kg body weight every 4 weeks from the 5th to the 33rd week of gestation. Complications occurred in only one patient who had gestational hypertension and abruptio placenta, while in the remaining 13 no maternal, fetal or neonatal complications were found, and the median birth weight was 3433 g. Similarly, a live-birth rate of 84% in 19 pregnancies of 15 patients with APS treated with monthly IVIg courses beginning in the first or early second trimester was reported by Clark et al. [51]. Pre-eclampsia occurred in 25% of the pregnancies, 75% of the infants were delivered at 34 weeks of gestation or later, there were no cases of intrauterine fetal growth retardation, and in seven pregnancies the IgG aCL titre decreased. In another report, 38 women with APS and at least three consecutive first trimester spontaneous abortions were treated with IVIg 300 mg/kg body weight at 3-week intervals beginning as soon as pregnancy had been confirmed until the 16th–17th week of pregnancy [52]. In 34 of 38 (89.4%) the pregnancy proceeded beyond the first trimester, while 31 of 38 (81.4%) gave birth to a healthy child at term.

The clinical manifestations associated with aPL progressively expand [53], and one of these clinical entities is infertility, as most studies report an increased prevalence of aPL in infertile women [54]. Sher et al. [55] tested whether aPL-positive infertile women undergoing in vitro fertilization (IVF) could benefit more from IVIg. Their population study included 89 infertile women who had experienced at least four IVF/embryo transfer failures, of whom 52 were aPL positive and 37 were aPL negative. All 89 patients received daily aspirin 81 mg, daily heparin 10 000 U, and a single infusion of IVIg involving 200 mg/kg body weight at the 17th week of pregnancy, with an additional 200 mg/kg every 4 weeks until the 33rd week of gestation. No significant differences were found in terms of pregnancy outcome or maternal complications among the treated and control groups. These findings are consistent with previous studies showing the lack of efficacy of IVIg in the treatment of APS-related complications.
IVIg therapy in APS—future aims

The therapeutic options for APS progressively increase and include (both experimental and clinical): aspirin, heparin, thromboxane A<sub>2</sub> receptor antagonists, interleukin-3, bromocriptine, anti-CD4 monoclonal antibodies, bone marrow transplantation, anti-idiotypes and IVIg [57]. Future research on the therapy of APS should concentrate on adjustments of the most efficient therapeutic regimen to certain clinical and laboratory manifestations of APS. As thrombosis is probably the most prominent pathological basis of APS, and one can claim that in that case anticoagulation (e.g. aspirin and heparin) would suffice, the report by Sher et al. [56] contributes to the understanding that in certain patient subgroups IVIg might have an additive effect to anticoagulation. Moreover, the detrimental effects of aPL should also be attributed to mechanisms other than thrombosis, as aCL was found to have an inhibitory effect on the pulsatility of placental secretion of human chorionic gonadotrophin during early pregnancy [58], and a direct inhibitory effect on trophoblast cells [59], which may affect the fate of the embryo. Anticoagulation would probably have no effect on these mechanisms of action of aPL, whereas IVIg that neutralizes these antibodies might have. Hence, in the current available therapeutic options, more data should be obtained in order to decide when to use anticoagulation, IVIg or both in the treatment of APS.

References

et al. 23. Blank M, Tincani A, Shoenfeld Y. Induction of anti phospholipid syndrome: immunological changes associated
19. Carreras LO, Perez GN, Vega HR, Casavilla F. Lupus anti-coagulant and recurrent fetal loss: successful treatment
18. Silver RK, Adler L, Hageman JR, Hickman AR. In vivo activity of intravenous gamma-antilupus anticoagulant and
1558 IVIg in APS


